Introduction
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Re-Evaluation of the Architecture Built During the 1920-1940 Period In
Re-evaluation of the Architecture built during the 1920-1940 period in Meran/o, South Tyrol, Italy. A dissertation submitted to Manchester School of Architecture, a joint school between The University of Manchester and Manchester Metropolitan University, for the degree of Master of Architecture (MArch RIBA Part II) Vanessa Torri 15110222 Manchester School of Architecture Academic Year 2015/2016 DECLARATION This dissertation is the author’s original work and no portion of the work referred to in the dissertation has been submitted in support of an application for another degree or qualification of this or any other university or other institute of learning. INTELLECTUALPROPERTY STATEMENT i. The author of this dissertation (including any appendices and/or schedules to this dissertation) owns certain copyright or related rights in it (the “Copyright”) and s/he has given The University of Manchester certain rights to use such Copyright, including for administrative purposes. ii. Copies of this dissertation, either in full or in extracts and whether in hard or electronic copy, may be made only in accordance with the Copyright, Designs and Patents Act 1988 (as amended) and regulations issued under it or, where appropriate, in accordance with licensing agreements which the University has entered into. This page must form part of any such copies made. iii. The ownership of certain Copyright, patents, designs, trademarks and other intellectual property (the “Intellectual Property”) and any reproductions of copyright works in the dissertation, for example graphs and tables (“Reproductions”), which may be described in this dissertation, may not be owned by the author and may be owned by third parties. -
31St International Epilepsy Congress Istanbul, Turkey 5Th – 9Th September 2015
ABSTRACTS 31st International Epilepsy Congress Istanbul, Turkey 5th – 9th September 2015 Epilepsia, 56(Suppl. 1):3–263, 2015 doi: 10.1111/epi.13241 Platform Session: Basic Science 0002 Sunday, 6th September 2015 MORPHOLOGICAL CHANGES IN EEG, AQUAPORIN- 4, C-FOS AND THE HIPPOCAMPUS OF ANIMAL 0001 MODELS WITH TEMPORAL LOBE EPILEPSY SODIUM SELENATE RETARDS EPILEPTOGENESIS INDUCED BY KAINIC ACID ı † † † ‡ VIA ACTIVATING PROTEIN PHOSPHATASE 2A E. Taskiran*,C.Ylmaz , N. Orhan , M. Bahceci , M. Kaya , B. Ahishali‡, M. Kucuk†, N. Arican‡, C. Gurses§ P. Zheng*, S. Liu*, N. Jones*, S. Shultz*, G. Dezsi*, D. Wright†, *Neurology Department, Istanbul Medipol University, Istanbul, C. Hovens‡, T.J. O’Brien*,§ † *The Royal Melbourne Hospital, Medicine, Melbourne, Turkey, Istanbul University, Research Institute of Experimental Medicine, Istanbul, Turkey, ‡Istanbul University Istanbul Australia, †The Florey Institutes of Neuroscience and Mental Faculty of Medicine, Istanbul, Turkey, §Department of Health, Melbourne, Australia, ‡The Royal Melbourne Hospital, Surgery, Melbourne, Australia, §Melbourne Brain Centre, Neurology and Clinical Neurophysiology, Istanbul University, Neurology, Melbourne, Australia Istanbul Faculty of Medicine, Istanbul, Turkey Purpose: Temporal lobe epilepsy (TLE) is the most frequent type of Purpose: Epileptogenesis describes the neurobiological processes that localization-related focal epilepsy seen in humans. It has a frequency rate convert a healthy brain into an epileptic brain. There are no treatments of 30–35% among all epilepsies, and comprises 70% of intractable available to mitigate epileptogenesis in clinical practice. Down-regula- epilepsies. With hippocampal sclerosis as the most often observed tion of protein phosphatase 2A (PP2A) activity increases phosphorylated histopathological finding, its epileptogenesis is still researched. tau (p-tau), which is implicated in acquired epilepsy. -
001 | Cerebrospinal Fluid Profile in Epilepsy Considering Exclusion Of
DOI: 10.1111/epi.14612 ABSTRACT ADULT EPILEPTOLOGY etiology and seizure type. This is most important to prevent 27 AUGUST 2018 misinterpretation of postictal phenomena of CSF parame- ters. Nevertheless, one should note, that mild pleocytosis 001 | Cerebrospinal Fluid Profile in Epilepsy and/or intrathecal Ig is found only in a minor percentage of patients, indicating careful exclusion of alternative reasons Considering Exclusion of an Autoimmune Origin for alterations in CSF profile. M. Süße*, N. Saathoff†, M. Hannich*, C. Holbe*, A. Dressel‡, A. Flöel§, F. von Podewils* *University Medicine Greifswald, Neurology/Epileptology, Greifswald, Germany; †University Medicine Greifswald, Greifswald, Germany; 002 | Automated Free‐Water Imaging Analysis ‡ § Carl‐Thiem Klinikum Cottbus, Neurology, Cottbus, Germany; University in Patients with Epilepsy and Focal Cortical Medicine Greifswald, Neurology, Greifswald, Germany Dysplasia Purpose: Analyzing cerebrospinal fluid (CSF) is crucial in B.A.K. Kreilkamp*,†, O. Pasternak‡, K. Das†, U.C. Wieshmann†, † ,† ,† the diagnostic workup of epileptic seizures, in particular to S. Biswas , A.G. Marson* , S.S. Keller* *University of Liverpool, Liverpool, United Kingdom; †The Walton Centre investigate the occurrence of infectious diseases or autoim- ‡ mune epilepsy in cases of encephalitis. It is, therefore, essen- NHS Foundation Trust, Liverpool, United Kingdom; Harvard Medical School, Boston, ME, United States tial to characterize CSF changes caused by epileptic seizures to understand etiological associated pathogenic alterations in Purpose: Focal cortical dysplasia (FCD) may escape neuro- CSF profile. Existing systematic investigations differ in radiologist assessment [Martin et al. QIMS 2015;5(2):188– result and methodology; also the systematic exclusion of 203]. Quantitative lesion detection usually relies on T1w and autoimmune encephalitis is lacking in present studies. -
Literatur-Dauerrecherche Multiple Sklerose Ausgabe Februar 2018
Literatur-Dauerrecherche – 1 – Multiple Sklerose: Veröffentlichungen Oktober 2013 Literatur-Dauerrecherche Multiple Sklerose Ausgabe Februar 2018 Die Literatur-Dauerrecherche finden Sie zum Download auch auf unserer Internetseite http://www.betaferon.de nach der Anmeldung unter dem Reiter „Aktuelle Informationen“, Menüpunkt „MS-Literaturupdate“. Bayer Vital GmbH, Specialty Medicine http://www.gesundheit.bayer.de http://www.betaferon.de Ungefiltert, unredigiert und nach Journals sortierthttp://www.ms -gateway.de Quelle: Public Medline; 288 Abstracts (=Neuaufnahmen in der Literaturdatenbank) Längste Therapieerfahrung 1,2,3,4 EDSS – Berufstätigkeit – Kognition BETAPLUS® Persönliche Patienten-Betreuung BETACONNECT® Innovative Injektionshilfe MEHR ALS 25 JAHRE KLINISCHE ERFAHRUNG 1 Goodin D et al., Neurology 2012;78:1315–1322, 2 Ebers G et al., JNNP 2010;81:907-912, 3 Kappos L et al.,Poster M1715WIP, ANA 2014, 4 Edan G et al., Poster P7.012,AAN 2015 Betaferon® 250 Mikrogramm/ml, Pulver und Lösungsmittel zur Herstellung einer Injektionslösung. Wirkstoff: Interferon beta-1b (Vor Verschreibung bitte die Fachinformation beachten.) Zusammensetzung: Arzneilich wirksamer Bestandteil: 1 ml der gebrauchsfertigen Injektionslösung enthält 250 Mikrogramm (8,0 Mio. I.E.) rekombinantes Interferon beta-1b. 1 Durchstechfl asche enthält 300 Mikrogramm (9,6 Mio. I.E.) rekombinantes Interferon beta-1b. Sonstige Bestandteile: Pulver für Injektionslösung: Albumin vom Menschen, Mannitol, Lösungsmittel: Natriumchloridlösung 0,54 % G/V. Anwendungsgebiete: Betaferon® -
Programme 2015
London on View The 5th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures 9-11 April 2015 London, United Kingdom Final Programme www.statusepilepticus2015.eu PATRONS Paracelsus Medical University Christian Doppler Klinik Ignaz Harrer Strasse 79 A-5020 Salzburg, Austria University College London Institute of Neurology Queen Square London WC 1N 3BG United Kingdom CHAIRS Simon Shorvon, London, United Kingdom Eugen Trinka, Salzburg, Austria 3 Contents Welcome Dear friends and colleagues, WELCOME ......................................................................................................................................... 5 Eugen Trinka Simon Shorvon GENERAL INFORMATION. ................................................................................................................ 6 It is our sincere pleasure to welcome you all to London, to this the 5th London-Innsbruck Col- Information FOR SPEAKERS & POSTER PRESENTERS................................................................... 8 loquium on Status Epilepticus and Acute Seizures. These meetings have taken place biennially since 2007, and have become an important fea- SCIENTIFIC PROGRAMME.................................................................................................................. 9 ture of the epilepsy calendar. ThursdaY, 9 APRIL 2015 ................................................................................................... 9 This year, the conference will focus on the clinical and experimental nature of status epilepti- cus